Jacek K. Pinski, MD, PhD

Associate Professor of Medicine

Image of Jacek K. Pinski, MD, PhD
Is this your profile? Click to edit

Overview

After completing a fellowship at the Johns Hopkins Cancer Center in Baltimore, Dr. Pinski came to the Keck School of Medicine at USC as an Assistant Professor of Medicine. A former Research Assistant Professor at the Endocrine, Polypeptide and Cancer Institute at the Tulane University School of Medicine, Dr. Pinski is currently the Co-Director of the USC/Norris Comprehensive Cancer Center’s Prostate Cancer Research Center.

Dr. Pinski is also a member of the Rehabilitation Research and Development Section for the United States Department of Veteran Affairs. He has received funding for seven research studies and in 2006 was invited to lecture in Austraila at the 3rd Annual Pacific Rim Breast and Prostate Cancer Meeting. Dr. Pinski has had over 60 peer reviewed articles published and has given presentations all across the globe.

Awards

  • GlaxoSmithKline: Fellowship Award, 2001
  • Johns Hopkins University: Fellowship Research Award, 2001
  • American Association for Cancer Research: Translational Research Award, 2001
  • Stop Cancer Award Special Seed Award, 2001
  • Wright Award, 2002
  • ACS/IRG Award, 2002
  • Whitney Award, 2002
  • Stop Cancer Research Career Development Award, 2002

Research Funding

  • Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial
    NIH · R01CA172436 · Sep 10, 2014 – Aug 31, 2021 · Role: Co-Principal Investigator
  • Targeted Therapy to Receptors for LH-RH in Prostate Cancer
    NIH · R01CA148756 · Sep 1, 2010 – Aug 31, 2015 · Role: Principal Investigator
  • AR signaling in Hormone Refractory Prostate Cancer
    NIH · R21DK065259 · Aug 1, 2003 – Jul 31, 2005 · Role: Principal Investigator

Publications

  • Feasibility of the Golf Recreational Exercise for Enhanced Survivorship in prostate cancer survivors undergoing hormone therapy. Front Oncol. 2026; 16:1844481.. View in PubMed
  • Transcription Factor-Mediated Reprogramming of Cancer-Associated Fibroblasts Reveals Targetable Vulnerabilities in Solid Tumors. bioRxiv. 2026 Apr 20.. View in PubMed
  • Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 10 01; 7(10):e2437871.. View in PubMed
  • Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clin Cancer Res. 2021 04 01; 27(7):1967-1973.. View in PubMed
  • A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemother Pharmacol. 2021 04; 87(4):525-532.. View in PubMed
  • Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2021 03; 24(1):61-68.. View in PubMed
  • Expression of the luteinizing hormone receptor (LHR) in ovarian cancer. BMC Cancer. 2019 Nov 15; 19(1):1114.. View in PubMed
  • Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer. 2019 11 01; 125(21):3853-3863.. View in PubMed
  • Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 08; 17(4):241-247.e1.. View in PubMed
  • A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51.. View in PubMed